DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-222/S-009

Purdue Pharmaceutical Products, L.P.
Attention: Beth Connelly
Senior Manager, U.S. Regulatory Affairs
One Stamford Forum
Stamford, CT 06901-3431

Dear Ms. Connelly:

Please refer to your supplemental new drug application dated June 28, 2005, received June 30, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Spectracef® (cefditoren pivoxil) tablets, 200 mg.

This "Changes Being Effected" supplemental new drug application provides for revisions to the ADVERSE EVENTS section, Postmarketing Experience subsection of the package insert for Spectracef®.

We completed our review of this application, and it is approved effective on the date of this letter for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed package insert submitted June 28, 2005.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 21-222/S-009.**" Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Janice M. Soreth, MD
Director,
Division of Anti-Infective and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure: Labeling submitted June 28, 2005

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Janice Soreth

12/20/2005 04:42:12 PM